ScholarIQanswers from OpenAlex & ORCID
Peter McLaughlin
ResearcherPublications, citations & collaboration network
Peter McLaughlin is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Peter McLaughlin have?
ScholarIQindexed works
Peter McLaughlin has 597 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Peter McLaughlin have?
ScholarIQcitation count
Peter McLaughlin has 26,230 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Peter McLaughlin?
ScholarIQh-index
Peter McLaughlin has an h-index of 84 in OpenAlex.
What is the i10-index of Peter McLaughlin?
ScholarIQi10-index
Peter McLaughlin has an i10-index of 314 in OpenAlex.
What is the ORCID of Peter McLaughlin?
ScholarIQorcid
The ORCID for Peter McLaughlin is on the source record.
What is the OpenAlex record for Peter McLaughlin?
ScholarIQopenalex
The OpenAlex for Peter McLaughlin is on the source record.
What are the most-cited papers on Peter McLaughlin?
ScholarIQmost cited works
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
Peter McLaughlin, A.J. Grillo-López, Brian K. Link, Ronald Levy, M. S. Czuczman, Michael E. Williams, Meyer R. Heyman, Isabelle Bence‐Bruckler, Christine A. White, Fernando Cabanillas, Vinay Jain, Anthony D. Ho, John Lister, Ken Wey, Diying Shen, B.K. Dallaire
Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project
Massimo Federico, Monica Bellei, Luigi Marcheselli, Stefano Luminari, Armando López‐Guillermo, Umberto Vitolo, Barbara Pro, Stefano Pileri, Alessandro Pulsoni, Pierre Soubeyran, Sergio Cortelazzo, Giovanni Martinelli, Maurizio Martelli, Luigi Rigacci, Luca Arcaini, Francesco Di Raimondo, Francesco Merli, Elena Sabattini, Peter McLaughlin, Philippe Solal‐Céligny
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial
Michael Wang, Luis Fayad, Nicolaus A. Wagner‐Bartak, Liang Zhang, Fredrick Hagemeister, Sattva S. Neelapu, Felipe Samaniego, Peter McLaughlin, Michelle A. Fanale, Anas Younes, Fernando Cabanillas, Nathan Fowler, Kate J. Newberry, Luhong Sun, Ken H. Young, Richard E. Champlin, Larry W. Kwak, Lei Feng, Maria Badillo, Maria Teresa Bejarano, Kimberly Hartig, Wendy Chen, Yi‐Ming Chen, Catriona Byrne, Neda Bell, Jerome B. Zeldis, Jorge Romaguera